financetom
Business
financetom
/
Business
/
Waste management firm Quest Resource's Q3 revenue beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Waste management firm Quest Resource's Q3 revenue beats estimates
Nov 10, 2025 1:55 PM

Overview

* Quest Resource ( QRHC ) Q3 revenue down 13% yr/yr but beats analyst expectations

* Adjusted EBITDA for Q3 beats consensus, showing operational improvements

* Company reduced debt by $4.6 mln in Q3, improving financial stability

Outlook

* Quest Resource ( QRHC ) did not provide specific financial guidance for future periods

Result Drivers

* OPERATIONAL EXCELLENCE - Initiatives improved sales team productivity and vendor management, enhancing financial results

* DEBT REDUCTION - Reduced debt by $4.6 mln in Q3, contributing to financial stability

* NEW CONTRACT - Signed a new contract in the food products end market, driving organic growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $63.30 $59.83

Revenue mln mln (3

Analysts

)

Q3 Beat $2.90 $2.35

Adjusted mln mln (3

EBITDA Analysts

)

Q3 Gross 18.10%

Margin

Q3 Gross $11.50

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the environmental services & equipment peer group is "buy"

* Wall Street's median 12-month price target for Quest Resource Holding Corp ( QRHC ) is $3.00, about 51.7% above its November 7 closing price of $1.45

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vestis Names New Chief Financial Officer, Chief Legal Officer
Vestis Names New Chief Financial Officer, Chief Legal Officer
Jan 31, 2025
08:08 AM EST, 01/31/2025 (MT Newswires) -- Vestis ( VSTS ) said Friday it has named Kelly Janzen its chief financial officer, starting Feb. 14. Janzen, who has worked with Vestis ( VSTS ) as a finance consultant since October 2024, previously had served as finance executive in residence at Fernweh Group and CFO for Dabico Airport Solutions from January...
Canadian bitcoin miner Bitfarms mulls pivot to AI data centers
Canadian bitcoin miner Bitfarms mulls pivot to AI data centers
Jan 31, 2025
(Reuters) - Toronto-based bitcoin miner Bitfarms ( BITF ) has enlisted two consultants to explore how it can transform some of its facilities to meet the growing demand for artificial intelligence data centers, it said on Friday. WHY IT'S IMPORTANT Crypto miners often own large plots of land and significant power resources - assets that are also crucial for high-performance...
Explainer-Trump's Mexico tariff threats: what has been said and what would the impact be?
Explainer-Trump's Mexico tariff threats: what has been said and what would the impact be?
Jan 31, 2025
MEXICO CITY (Reuters) - If U.S. President Donald Trump follows through on his pledge to slap 25% tariffs on imports from Mexico it could usher in a volatile new chapter in the longstanding trade relationship with the impacts hitting consumers. Mexico is the United States' largest trading partner, representing over 15% of total trade. The U.S. imported more than $475...
Biogen, Eisai Say EU Panel Set to Discuss Additional Safety Data on Lecanemab
Biogen, Eisai Say EU Panel Set to Discuss Additional Safety Data on Lecanemab
Jan 31, 2025
08:09 AM EST, 01/31/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use is expected to discuss in February additional safety data on lecanemab as treatment for early Alzheimer's disease. The committee recommended the approval of lecanemab in November 2024, but was asked by the European Commission to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved